Comparison of ALD, NASH, and Healthy Control Patients
The Cleveland Clinic · NCT03224949
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–75 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 500
- US sites recruiting
- 1
- Study start
- June 19, 2017
- Record last updated
- September 25, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The availability of biological samples from individuals with alcoholic liver disease (ALD), as well as samples from appropriate heavy drinking, yet healthy controls and non-drinking healthy controls, is an essential first step in the translation of basic research advances to the clinic. The purpose of the Clinical Core component of the P50 Northern Ohio Alcohol Center (NOAC) is to provide biological samples (plasma/serum, buffy coats, and urine) from patients with different stages of alcoholic liver disease, as well as healthy control subjects, to members of the NOAC. These samples can then be used to test specific hypotheses related to the presence of specific biomarkers in the serum, functional immune activity in PBMCs and/or genetic polymorphisms that may predict severity of disease, short- and long-term morbidity and mortality and/or responsivity to specific therapeutic interventions commonly used in clinical practice. This study is building on the established biorepositories and the diversity of outstanding clinical expertise at the Cleveland Clinic. This biorepository included clinical samples (plasma, serum, buffy coats, and urine) from patients with different stages of ALD and subjects who are heavy drinkers without ALD, recruited from the Cleveland Clinic alcohol use disorder treatment clinic. This study will be responsible for collecting more data to help build the CCF-ALD biorepository via subject recruitment and communication and specimen collection.
Being studied: Blood draw
Conditions: ALD - Alcoholic Liver Disease
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Alcoholic Steatosis Patients
Inclusion
- Fat accumulation (Steatosis) without signs of fibrosis/ inflammation in patients with alcohol abuse (alcohol intake >60 g/day in men and >40 g/day in women)
- Abnormal liver serum tests indicative of liver disease (elevated AST>ALT, y-glutamyl transpeptidase and bilirubin) .
Alcoholic Hepatitis with Mild Fibrosis
Inclusion
- Steatosis plus hepatocellular damage (presence of Mallory bodies and hepatocellular ballooning)
- Polymorphonuclear infiltrate
- Fibrosis stage 1-2
Alcoholic Hepatitis with Advanced Fibrosis
Inclusion
- Steatosis plus hepatocellular damage (presence of Mallory bodies and hepatocellular ballooning)
- Polymorphonuclear infiltrate
- Fibrosis stage 3-4.
Alcoholic Cirrhosis
Inclusion
- Fibrosis stage 4
- Presence of complications of cirrhosis such as esophageal varices with our without a previous episode of bleeding, splenomegaly, ascites, hepatic corroborate the diagnosis of cirrhosis.
Alcoholic Cirrhosis with HCC
Inclusion
-Diagnostic criteria of cirrhosis and established HCC. The diagnosis of HCC will be established based on histological confirmation or contrast-enhanced radiographic imaging according to the AASLD recommendations.
Exclusion
- BMI>35
- HBV
- Hemochromatosis
- Wilson's disease
- Autoimmune hepatitis
- Drug-inducted liver disease
- Hepatitis C
- Antitrypsin deficiency
- Patients who do not sign informed consent.
Non-alcoholic steatohepatitis
Inclusion -Biopsy proven NASH and chronic liver disease due to HCV patients.
Exclusion
- Cancer
- Diabetes
- Hypertension
- CAD or stroke
- Past history of liver disease
- Hepatitis C
- Antitrypsin deficiency
- Alcohol consumption of less than 7 drinks per week for women and less than 14 drinks per week for men
- BMI >35.
Healthy controls
Inclusion
-AUDIT-C score less than 4 in men and less than 3 in women.
Exclusion
- Cancer (except of non-melanoma skin cancer)
- Diabetes
- Hypertension
- Hypercholesterolemia
- Coronary artery disease or stroke
- History of current or past liver disease of any etiology
- BMI >27Kg/m2
Recruiting US locations
Cleveland Clinic Foundation
Cleveland, OH 44195
Site contact: Annette Bellar, BS · 216-636-5247 · bellara@ccf.org
Study contacts (from the official record)
- Annette Bellar, MSLA · 216-636-5247 · bellara@ccf.org
- Revathi Penumatsa, MD · 216 445-0688 · penumar@ccf.org
Similar studies in Ohio
All nutrition & metabolism studies in Ohio →- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Hoffmann-La Roche
- Location
- Akron, OH + 112 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 4
Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients
Fresenius Kabi
- Location
- Columbus, OH + 3 other US sites
- Eligibility basics
- Ages 1 mo–17
- RecruitingPhase 4
Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis
Madrigal Pharmaceuticals, Inc.
- Location
- Cincinnati, OH + 2 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
Pfizer
- Location
- Cincinnati, OH + 4 other US sites
- Eligibility basics
- Ages 18+